GERN geron.com: Enterprise Value to EBITDA Ratio

Brandmark of Geron Corporation (GERN)

FDA approval of Rytelo has strengthened the patent moat of Geron Corporation (GERN) through unique telomerase inhibitors. The EV/EBITDA multiple in a historical context on the GURU.Markets chart demonstrates market trends, where the 0.00 mark serves as a key metric. Monopoly pricing power within the myelodysplastic syndromes therapy niche and the launch of an innovative drug provide the company with high margins and a stable inflow of free cash flow.

GERN Geron Corp.: Company Value to Operating Income Before Depreciation Ratio in the range 11/23/2025 - 11/12/2026

Metric breakdowns and analytics for geron.com (GERN)

- stock price and consensus target price:
Stock Quotes Geron Corp.|GERN - Average Forecast Price
- company stock capitalization data:
Market Valuation Geron Bio|GERN - Value Adjusted for Debt and Cash
- business book valuation details:
Net Assets per Single Share Geron|GERN - Net Asset Value|Market Value to Book Value Ratio geron.com|GERN - Aggregate Company Assets
- debt and solvency information:
Total Debt to Capital Geron Corporation|GERN - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio Geron|GERN - Company Cumulative Indebtedness|Debts to Book Capitalization Geron Bio|GERN - Long-Term Liabilities|Company Short-Term Debt Geron|Quick Liquidity geron.com
- business earnings and investment ratios data:
GERN - Final Profit|Expected Profit Geron Corporation|GERN - Price to Earnings Ratio|Future Price to Earnings Geron Corporation|GERN - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple Geron Bio|GERN - Operating profit before depreciation charges|Net earnings per share (EPS TTM) Geron|GERN - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months geron.com|GERN - Earnings per share increase in current year|Net earnings per share growth forecast for next year Geron Corporation
General company analysis:Geron Corp. GERN
Product sample of Geron Corp

For Geron Corporation, which is launching a drug in the hematology segment, it is critical to evaluate business value through the lens of EBITDA. This metric compares the total enterprise value with its ability to generate cash flow, neutralizing the impact of debt load and tax regimes. Analyzing the EV/EBITDA ratio alongside the capital structure allows for the determination of the issuer's fair value during its expansion in the US market.

Direct competitors

Nanobiotix Corp - Enterprise Value to EBITDA Ratio|Bicycle Corp (BCYC) - Company Value to EBITDA|CTMX: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation CATX (Perspective Therapeutics)|genelux.com (GNLX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio MOLN (Molecular Partners Ltd)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Oncolytics Biotech, Inc.|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization LSTA|EV/EBITDA Multiple MBRX|EV/EBITDA Multiple galeratx.com (GRTX)|Molecular Templates, Inc. - Enterprise Value to EBITDA Ratio